Qiagen donates 3,000 latent tuberculosis screening tests to Health Ministry

New partnership with Niba Labs to offer customized digital PCR (dPCR) assay design services to biopharma customers // Launch of CGT Viral Vector Lysis Kit enabling standardized workflow from cell lysa… Combating and keeping the disease under control requires testing as the first step towards early detection, as well as treatment for those who have contracted LTBI in order to break the cycle of transmission and infection of TB. KUALA LUMPUR, Sept 5 — Qiagen today announced the donation of 3,000 QuantiFERON-TB Gold Plus tests to the Ministry of Health (MoH) Malaysia as a diagnostic tool for latent tuberculosis infection (LTBI) screening. This screening is focused on assisting the check-ups of immunocompromised patients, a key risk group for tuberculosis (TB) disease, as part of Qiagen’s commitment to making a positive impact on underserved communities in eradicating tuberculosis. QIAGEN recently completed the full acquisition of Verogen for $150 million in cash paid from existing reserves. QIAGEN currently expects about $20 million of sales from the Verogen portfolio in 2023, building on about $5 million of sales for QIAGEN in 2022 from the distribution agreement.

Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. We note that hedge funds don’t have a meaningful investment in Qiagen. Looking at our data, we can see that the largest shareholder is BlackRock, Inc. with 14% of shares outstanding. For context, the second largest shareholder holds about 9.3% of the shares outstanding, followed by an ownership of 3.8% by the third-largest shareholder. Verogen is a dedicated developer of DNA-based biometric human identification products for analysis of forensic genomic samples.

Qiagen (QGEN) Surpasses Q2 Earnings and Revenue Estimates

Because of the lapsed offer, QIAGEN was required to reimburse $95 Million to Thermo Fisher in expenses.[37] Within a week of the collapse of the merger, QIAGEN’s stock rose over 10%. In 2017, QIAGEN acquired OmicSoft Corporation, a leading provider of highly curated public datasets. Qiagen shares surged 19% to 37.84 euros after Thermo Fisher Scientific said it would buy the diagnostics firm for 39 euros per share in cash, which is a 23% premium to Monday’s close. QGEN’s beta can be found in Trading Information at the top of this page.

Globally, QuantiFERON-TB Gold Plus has helped patients and providers reduce the number of doctor’s visits to a single blood draw with a faster turnaround time. Verogen, a privately held company founded in 2017 and based in San Diego, supports the global human identification community with NGS tools and professional services to help resolve criminal and missing-persons cases. QIAGEN and Verogen have been commercialization partners since announcing a distribution agreement in June 2021. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days.

Qiagen, Pandion See Activist Actions

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis.

Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of Famous investors your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. TB is regarded as a prevalent and serious public health concern in Malaysia, with an estimated 25,000 new cases reported each year.

Time to Upgrade!

But to truly gain insight, we need to consider other information, too. Every company has them, and we’ve spotted 1 warning sign for Qiagen you should know about. Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Denmark one of the first countries https://investmentsanalysis.info/ to implement whole-genome sequencing (WGS) as a standard-of-care for oncology and to adopt QCI Interpret to support the national initiative // QCI Interpret to be us… First-of-its-kind systematic review on the clinical relevance of test values from the QuantiFERON-TB Gold Plus TB1 and TB2 blood collection tubes has been published // Study including 4,050 subjects h…

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. Read our equity story, financial disclosures and how we create shareholder value. Up to date protocols and list of COVID-19 testing and research solutions.

What Does The Institutional Ownership Tell Us About Qiagen?

The Germany-based provider of sample and assay technologies now expects net sales to grow by at least 32%… As you can see, institutional investors have a fair amount of stake in Qiagen. This implies the analysts working for those institutions have looked at the stock and they like it. When multiple institutions own a stock, there’s always a risk that they are in a ‘crowded trade’.

Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm’s revenue (45% of 2021 sales), followed by EMEA (36%), and Asia-Pacific (19%). QIAGEN is targeting market segments with promising growth opportunities. At the core of this strategy is a focus on five pillars of growth which are built on the company’s leadership in sample technologies, the first step in any laboratory process. QuantiFERON-TB Gold Plus is the leading interferon-gamma release assay (IGRA) blood test, with millions of tests performed annually. International guidance from the World Health Organisation (WHO) support the use of blood tests like QuantiFERON-TB Gold Plus in all settings as part of the fight to end the global TB epidemic.

And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Qiagen’s second-quarter results mildly exceeded expectations, even when considering the significant COVID-19-related declines versus a tough comparable period in 2022. However, management trimmed its 2023 guidance due to more severe retrenching activities at some customers, similar to recent trends we have seen at other life science toolmakers. After adjusting our near-term assumptions a bit, we do not anticipate changing our fair value estimate for Qiagen at first glance.

• So they usually pay more attention to companies that are included in major indices.
• The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company.
• Working closely with the forensic community, Verogen places exceptional value on flexible, scalable solutions that deliver reliable results.
• At the core of this strategy is a focus on five pillars of growth which are built on the company’s leadership in sample technologies, the first step in any laboratory process.
• IT Client Prospector provides intelligence on Qiagen NV’s likely spend across technology areas enabling you to understand the digital strategy.
• According to 2 analysts, the average rating for QGEN stock is “Buy.” The 12-month stock price forecast is $54.0, which is an increase of 25.44% from the latest price.

Due to planned investments for commercialization and portfolio development, the transaction is expected to be dilutive to full-year 2023 adjusted EPS by about $0.03 per share and neutral to adjusted EPS in 2024. QIAGEN also gains full access to Verogen’s pioneering GEDmatch database and GEDmatch PRO™ portal. GEDmatch allows users to upload genetic profiles created by other genealogy sites in order to expand the search for familial links; it currently contains more than 1.8 million genealogical profiles and continues to grow. GEDmatch PRO™ is designed to support police and forensic teams with investigative comparisons to data uploaded by consenting GEDmatch users.

Thermo Fisher Scientific Inc

Qiagen NV shares plummeted more than 25% in late trading on Tuesday after the company announced that a strategic review had ended with a decision to not break up nor sell the business. Analytical instruments company Thermo Fisher Scientific Inc. reported Wednesday first-quarter profit and revenue that topped expectations, as revenue beats in its laboratory products, specialty diagnostics and life scienc… While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing.